Vertex Pharmaceuticals Inc. plans to up its gene editing game by expanding an existing collaboration with Crispr Therapeutics AG and acquiring privately held Exonics Therapeutics Inc. to develop therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).